| __timestamp | AstraZeneca PLC | Incyte Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 13324000000 | 165772000 |
| Thursday, January 1, 2015 | 11451000000 | 196614000 |
| Friday, January 1, 2016 | 9739000000 | 303251000 |
| Sunday, January 1, 2017 | 10543000000 | 366406000 |
| Monday, January 1, 2018 | 10362000000 | 434407000 |
| Tuesday, January 1, 2019 | 11848000000 | 468711000 |
| Wednesday, January 1, 2020 | 11693000000 | 516922000 |
| Friday, January 1, 2021 | 15680000000 | 739560000 |
| Saturday, January 1, 2022 | 18955000000 | 1002140000 |
| Sunday, January 1, 2023 | 18025000000 | 1161300000 |
| Monday, January 1, 2024 | 20532000000 | 1242157000 |
Unleashing the power of data
In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. AstraZeneca PLC and Incyte Corporation, two prominent players, have shown contrasting approaches over the past decade.
From 2014 to 2023, AstraZeneca's SG&A expenses have seen a significant increase, peaking at approximately $18 billion in 2022. This represents a growth of over 40% from their 2016 low. In contrast, Incyte Corporation has maintained a more conservative approach, with expenses rising from $166 million in 2014 to just over $1 billion in 2023, marking a sixfold increase.
While AstraZeneca's strategy reflects aggressive expansion and investment, Incyte's careful cost management highlights a focus on efficiency. This comparison offers valuable insights into how different strategies can impact financial health in the pharmaceutical sector.
Comparing SG&A Expenses: Merck & Co., Inc. vs AstraZeneca PLC Trends and Insights
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and Bristol-Myers Squibb Company
AstraZeneca PLC or Bio-Techne Corporation: Who Manages SG&A Costs Better?
AstraZeneca PLC vs Viking Therapeutics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: AstraZeneca PLC vs PTC Therapeutics, Inc. Trends and Insights
Comparing SG&A Expenses: AstraZeneca PLC vs ImmunityBio, Inc. Trends and Insights
Selling, General, and Administrative Costs: AstraZeneca PLC vs Viridian Therapeutics, Inc.
Selling, General, and Administrative Costs: Alnylam Pharmaceuticals, Inc. vs Incyte Corporation
BeiGene, Ltd. or Incyte Corporation: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Incyte Corporation and Ascendis Pharma A/S
Operational Costs Compared: SG&A Analysis of Incyte Corporation and Jazz Pharmaceuticals plc
Cost Management Insights: SG&A Expenses for Incyte Corporation and Corcept Therapeutics Incorporated